Showing 1 - 10 of 116
Persistent link: https://www.econbiz.de/10003700842
Persistent link: https://www.econbiz.de/10010198694
Persistent link: https://www.econbiz.de/10001765893
Generic drug prices have been the focus of much attention in recent years, with Congressional committees, executive agencies and private organizations all conducting investigations into the pricing patterns for generic drugs. Price spikes for selected old, off-patent drugs have also been widely...
Persistent link: https://www.econbiz.de/10012865747
We examine six molecules facing initial loss of US exclusivity (LOE, from patent expiration or challenges) between June 2009 and May 2013 that were among the 50 most prescribed molecules in May 2013. We examine prices per day of therapy (from the perspective of average revenue received by retail...
Persistent link: https://www.econbiz.de/10013062618
Generic drug prices have been the focus of much attention in recent years, with Congressional committees, executive agencies and private organizations all conducting investigations into the pricing patterns for generic drugs. Price spikes for selected old, off-patent drugs have also been widely...
Persistent link: https://www.econbiz.de/10012480066
Persistent link: https://www.econbiz.de/10012099433
Persistent link: https://www.econbiz.de/10011812699
The Bureau of Labor Statistics' Prescription Drug Consumer Price Index (CPI-Rx) has been the focus of considerable controversy in recent years. The CPI-Rx limits its sampling frame to transactions in retail outpatient outlets, and excludes prescription pharmaceuticals dispensed in hospitals,...
Persistent link: https://www.econbiz.de/10013388804
Persistent link: https://www.econbiz.de/10003498981